In this study, Kripke's claim, that within the framework of the possible worlds argument, the identification of mental processes by being reduced to physical events doesn't have an imperative base is addressed. Theories of physicalism and identity aims to explain the mental processes in a thoroughly physical way, thus trying to reduce it to the physical one, through brain events. According to Kripke, there must be an imperativeness for the identification of mental states with physical states. According to him, however, (...) it is not possible to show that physical events necessarily reveal mental processes. According to Kripke, in order to be imperatively correct for one statement, it must be correct in all possible worlds. Kripke uses the concept of "rigid designator" to describe this situation. According to Kripke, the thesis of identity between rigid designators must be metaphysically imperative correct. This situation does not apply to mental events. So then, the aim of this article is to reveal why the thesis of identity proposed in the explanation of physical and mental situations in terms of Kripke is not valid. (shrink)

Heidegger felsefesinin en temel niteliği, bize göre monistik bir karakter arz etmesidir. Heidegger'de varlık, hiçlik, zaman, metafizik terimleri hep aynı ontolojik problemin farklı terminolojik veçheleri olarak karşımıza çıkar. Sadece varlığı anlamaya hasredilmiş bu felsefenin başyapıtı ise kuşkusuz Varlık ve Zaman'dır. Bu eserde Heidegger titiz, ancak önceki felsefelerden farklı bir perspektif ile varlık sorusunu ele alır ve varlığı anlamaya çalışır. Varlığın yanı başında duran diğer bir kavram ise hiçliktir. Hiçlik problemini ise Heideger, bir ders sunumu olan Metafizik Nedir? isimli küçük risalesinde (...) irdeler. Ancak Metafizik Nedir?deki çözümlemelerin terminolojik arka planının önemli ölçüde Varlık ve Zaman'da olduğunu düşünüyoruz. Bu makalede filozofun Metafizik Nedir?’deki hiçlik çözümlemesi, Varlık ve Zaman’daki varlık çözümlemesi ile irtibatlı olarak ele alınıp anlaşılmaya çalışılacaktır. (shrink)

Heidegger’in en önemli ve bize göre diğer filozoflardan ayrılan en belirgin özelliği, düşüncelerini dile getirirken dilsel bağlamda yaptığı çözümlemeler ve oluşturduğu kavramsal yeniliklerdir. Ontolojisinin temeline yerleştirdiği ve insan varlığı anlamına gelen “Dasein” terimi de bunlardan biri, belki de en önemlisidir. Dasein, varlığın temeli, anlamı ve sonudur. Bunun yanı sıra tamamlanmamış bir varlıktır. Dasein’ın kendi varlığını ancak ölüm ile ikmal edeceğini öne süren Heidegger, bu durumu sum moribundus olarak kavramsallaştırır. Biz bu çalışmada “ölüme yönelik bir varlık olarak Dasein”ın özdeşliğine ulaşma imkânının (...) mahiyetini ve bu çerçevede Kartezyen özne ile olan ilişkisini ele almaya çalışacağız. (shrink)

1. cilt. Giriş, inceleme, tıpkıbasım -- 2. cilt. Tenkitli metin.

Hopfield neural network is considered as an artificial model derived from the brain structures and it is an important model that admits an adequate performance in neurocomputing. In this article, we solve a dynamical model of 3D HNNs via Atangana–Baleanu fractional derivatives. To find the numerical solution of the considered dynamical model, the well-known Predictor-Corrector method is used. A number of cases are taken by using two different sets of values of the activation gradient of the neurons as well as (...) six different initial conditions. The given results have been perfectly established using the different fractional-order values on the given derivative operator. The objective of this research is to investigate the dynamics of the proposed HNN model at various values of fractional orders. Nonlocal characteristic of the AB derivative contains the memory in the system which is the main motivation behind the proposal of this research. (shrink)

This study sought to determine cardiologists’ degrees of ethical awareness and preferred courses of action for ethical dilemmas frequently encountered in clinical settings. For this evaluation, an online survey was created and sent to cardiologists affiliated with various academic posts in Ankara, Turkey. The survey included ten cases with various ethical considerations selected from our book, “Clinic Ethics with Cases from Cardiology.” Four possible action choices were defined for each case. Participants were asked to choose one or more of these (...) preferences. In addition, a fictional change was made in each case’s context without changing the original ethical issue, and participants were asked whether an attitude different from the first chosen one was preferred. The participation ratio was 49/185 (26%), consent ratio 47/185 (25,4%), and completion ratio 44/185 (23,7%). Nine of the ten scenario changes did not change participants’ preferred action. For most questions, action preferences were concentrated between the two options. Although legal regulations did not reduce ethical dilemmas, they clarified physicians’ action preferences. Similarly, as an obscure moral issue gained prominence, physicians were forced to draw clearer lines in their actions. External factors such as healthcare emergencies can change physicians’ ethical dilemma-solving attitudes. (shrink)

BackgroundThe coronavirus disease (COVID-19) treatment must be based on scientific methods such as clinical trials. Trials involving human subjects and those requiring a risk-benefit analysis may occasionally face challenges owing to the time limitations in the pandemic. MethodologyThis study analyses the WHO's International Clinical Trials Registry Platform and clinicaltrials.gov, where most COVID-19 clinical trials are registered, according to ethical criteria including study design, conflicts of interest, enrollment of healthcare workers, study locations, site-, design-, and participant-related issues. The discussion is based (...) on three aspects: the quality of the information to be produced, the relevance to significant health problems, and the creation or evaluation of interventions, policies, or practices that promote individual or public health. ResultsThere were significant differences between the two platforms regarding the investigational medicinal product (IMP), the comparator, ethics committee/institutional review board approval, plan to share individual participant data, study phase, site, IMP, and design-related issues. Conflict of interest, sponsor information, and management of vulnerable groups were the main areas wherein both platforms lacked sufficient information. ConclusionWith this analysis, we aimed to define a minimum set of ethical criteria for clinical trial platforms to obtain standardization between these two platforms. (shrink)

BackgroundThe coronavirus disease (COVID-19) treatment must be based on scientific methods such as clinical trials. Trials involving human subjects and those requiring a risk-benefit analysis may occasionally face challenges owing to the time limitations in the pandemic. MethodologyThis study analyses the WHO's International Clinical Trials Registry Platform and clinicaltrials.gov, where most COVID-19 clinical trials are registered, according to ethical criteria including study design, conflicts of interest, enrollment of healthcare workers, study locations, site-, design-, and participant-related issues. The discussion is based (...) on three aspects: the quality of the information to be produced, the relevance to significant health problems, and the creation or evaluation of interventions, policies, or practices that promote individual or public health. ResultsThere were significant differences between the two platforms regarding the investigational medicinal product (IMP), the comparator, ethics committee/institutional review board approval, plan to share individual participant data, study phase, site, IMP, and design-related issues. Conflict of interest, sponsor information, and management of vulnerable groups were the main areas wherein both platforms lacked sufficient information. ConclusionWith this analysis, we aimed to define a minimum set of ethical criteria for clinical trial platforms to obtain standardization between these two platforms. (shrink)

BackgroundThe coronavirus disease (COVID-19) treatment must be based on scientific methods such as clinical trials. Trials involving human subjects and those requiring a risk-benefit analysis may occasionally face challenges owing to the time limitations in the pandemic. MethodologyThis study analyses the WHO's International Clinical Trials Registry Platform and clinicaltrials.gov, where most COVID-19 clinical trials are registered, according to ethical criteria including study design, conflicts of interest, enrollment of healthcare workers, study locations, site-, design-, and participant-related issues. The discussion is based (...) on three aspects: the quality of the information to be produced, the relevance to significant health problems, and the creation or evaluation of interventions, policies, or practices that promote individual or public health. ResultsThere were significant differences between the two platforms regarding the investigational medicinal product (IMP), the comparator, ethics committee/institutional review board approval, plan to share individual participant data, study phase, site, IMP, and design-related issues. Conflict of interest, sponsor information, and management of vulnerable groups were the main areas wherein both platforms lacked sufficient information. ConclusionWith this analysis, we aimed to define a minimum set of ethical criteria for clinical trial platforms to obtain standardization between these two platforms. (shrink)

BackgroundThe coronavirus disease (COVID-19) treatment must be based on scientific methods such as clinical trials. Trials involving human subjects and those requiring a risk-benefit analysis may occasionally face challenges owing to the time limitations in the pandemic. MethodologyThis study analyses the WHO's International Clinical Trials Registry Platform and clinicaltrials.gov, where most COVID-19 clinical trials are registered, according to ethical criteria including study design, conflicts of interest, enrollment of healthcare workers, study locations, site-, design-, and participant-related issues. The discussion is based (...) on three aspects: the quality of the information to be produced, the relevance to significant health problems, and the creation or evaluation of interventions, policies, or practices that promote individual or public health. ResultsThere were significant differences between the two platforms regarding the investigational medicinal product (IMP), the comparator, ethics committee/institutional review board approval, plan to share individual participant data, study phase, site, IMP, and design-related issues. Conflict of interest, sponsor information, and management of vulnerable groups were the main areas wherein both platforms lacked sufficient information. ConclusionWith this analysis, we aimed to define a minimum set of ethical criteria for clinical trial platforms to obtain standardization between these two platforms. (shrink)

The fortress of Kelefa on the western side of the Mani peninsula in southern Greece is one of a series of fortifications constructed or refurbished to defend the Ottomans' maritime frontier against Venice in the late seventeenth century. This chapter addresses whether the castle is indeed of Ottoman construction, or whether it is in fact an earlier, Frankish, structure that was merely restored by the Ottomans. It outlines what The Chronicle of the Morea says and how it can be interpreted. (...) It looks at what light later literary and other sources can throw on the problem, discussing Evliya Çelebi in the process. It identifies Grand Magne with a fortress which others have claimed is of Ottoman construction and dates from the seventeenth rather than the thirteenth century. The chapter also provides a sketch of the Mani as part of the Ottoman frontier zone in the Mediterranean region. (shrink)